Drug Trial Radar · NCT05007977
Effect of ZT-01 on Glucagon During Hypoglycemia in Type 1 Diabetes Mellitus
Last checked: Nov 19, 2026Latest source record: Jul 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
24
Actual
Start
Jul 8, 2021
Primary completion
Apr 12, 2022
Study completion Apr 18, 2022
Sponsor
- Lead sponsor
- Zucara Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 17, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether ZT-01 increases the glucagon response to hypoglycemia in type 1 diabetes (T1D). ZT-01 is a specific somatostatin (SST) type 2 receptor antagonist hypothesized to increase the counterregulatory glucagon release during hypoglycemia, which is impaired in diabetes, and may thus reduce the occurrence of hypoglycemia. Approximately 25 participants with well-controlled type 1 diabetes will be recruited to a crossover study and be randomized to the order in which they receive a single administration of placebo, low dose and high dose ZT-01 during three euglycemic-hypoglycemic clamps 2 to 6 weeks apart, with a follow-up visit approximately 1 week after the final clamp. Participants will stay overnight in the clinic before each clamp, and their plasma glucose (PG) will be kept at euglycemic levels with IV insulin and dextrose as needed. The following morning, the clamp will begin and the subject's PG will be kept at 5.5 mmol/L (euglycemia) with variable IV insulin (and dextrose as needed). Study treatment will be administered during this euglycemic period, and then insulin will be increased so that PG falls to a plateau of mild hypoglycemia, and then increased further to clinically significant hypoglycemia. Release of glucagon and other counterregulatory hormones will be measured, and a symptom score will be completed, during euglycemia before and following study treatment, and during each level of hypoglycemia. Following the clamp, the participant's blood glucose will be returned to normal levels prior to leaving the clinic.
Conditions
- Type 1 Diabetes
- Hypoglycemia
Interventions
ZT-01 low doseDrug
Single subcutaneous (SC) injection of ZT-01 3 mg during hypoglycemic clamp
ZT-01 high doseDrug
Single SC injection of ZT-01 20 mg during hypoglycemic clamp
PlaceboDrug
Single SC injection of placebo during hypoglycemic clamp
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in glucagon between euglycemia and hypoglycemiaTime frame: During each clamp, up to 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
LMC Manna Research
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.